MedPath

Detection of Immunotoxic Gluten Peptides in Feces

Completed
Conditions
Celiac Disease
Interventions
Other: Detection of gluten in feces
Registration Number
NCT01478867
Lead Sponsor
University of Seville
Brief Summary

The purpose of this study is to monitor of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces.

Detailed Description

Certain immunotoxic peptides from gluten are resistant to gastrointestinal digestion and can interact with celiac patient factors to trigger immunological response. Gluten-free diet (GFD) is the only effective treatment for celiac disease (CD) and its compliance should be monitored to avoid accumulative damage. However, practical methods to monitor diet compliance and to detect the origin of an outbreak of celiac clinical symptoms are not available.

This study assesses the capacity to determine the gluten ingestion, and to monitor the GFD compliance in celiac patients by detection of gluten and gliadin 33-mer equivalent peptidic epitopes in human feces.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
53
Inclusion Criteria
  • Celiac patient
  • 1-12 years old
  • Written informed consent
Exclusion Criteria
  • Known inflammatory bowel diseases
  • Participation in any other studies involving investigational concomitantly or within two weeks prior to entry into the study and during the course of the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Celiac patientsDetection of gluten in feces-
Primary Outcome Measures
NameTimeMethod
Monitoring of gluten-free diet compliance in celiac patientsApril-July 2011 (3 months)

Usual gluten diet for celiac (home diet not modified for this trial)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville

🇪🇸

Seville, Spain

© Copyright 2025. All Rights Reserved by MedPath